Evaluation of Safety and Preliminary Efficacy of IL12-L19L19 in Patients with Advanced or Metastatic Carcinomas Post-Immune Checkpoint Blockade Therapy

The primary objective of this study is to evaluate the **safety** and early signs of efficacy of IL12-L19L19 in patients with advanced or metastatic carcinomas who have previously undergone immune checkpoint blockade therapy. This is clinically relevant as it aims to determine the potential of IL12-L19L19 to provide therapeutic benefits in a population with limited treatment options due to the progression of disease despite prior immunotherapy.

The clinical trial involves a total of **38 participants** diagnosed with **advanced or metastatic carcinomas** following previous immune checkpoint blockade therapy. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective or specific inclusion criteria for the study.

The clinical trial is designed to evaluate the **safety** and early signs of efficacy of IL12-L19L19 in patients with advanced or metastatic carcinomas who have previously undergone immune checkpoint blockade therapy. This trial is structured as a Phase 1 study, which is typically focused on assessing the safety profile of the investigational product and identifying any potential adverse effects. The trial is expected to run from May 27, 2020, to July 31, 2026, providing a comprehensive timeline for data collection and analysis.

The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to either the treatment group receiving IL12-L19L19 or a control group, with neither the participants nor the investigators aware of the group assignments. This approach minimizes bias and enhances the objectivity of the findings.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be enrolled in the study and attend regular follow-up visits to monitor their health status, assess the treatment's effects, and collect necessary data. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to evaluate the overall impact of the treatment.

The expected length of participant involvement will vary depending on individual response to the treatment and the occurrence of any adverse events. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed necessary by the investigators. The trial's design and procedures are meticulously planned to ensure the safety and well-being of participants while providing valuable insights into the potential benefits of IL12-L19L19 for this patient population.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on May 27, 2020, with an estimated completion date of July 31, 2026. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize various parameters such as **biomarker** levels or symptom improvement scores to gauge initial efficacy signals. The methods for measuring and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes collected at predetermined timepoints throughout the study duration. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy data collected.